Certoparin sodium

Drug Profile

Certoparin sodium

Alternative Names: Certoparin; Mono-Embolex; Sandoparin; Sandoparine; Troparin

Latest Information Update: 21 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Antithrombotics; Low molecular weight heparins
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Deep vein thrombosis; Pulmonary embolism; Thromboembolism

Most Recent Events

  • 06 Sep 2015 Launched for Thromboembolism (Prevention) in India (SC) before September 2015
  • 03 Feb 2015 Launched for Thromboembolism (Prevention) in Austria (SC) before February 2015
  • 26 Jan 2015 Aspen Global Incorporated acquires certoparin sodium from Novartis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top